These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 8625036)

  • 1. Epirubicin, cisplatin, and continuous infusion 5-fluorouracil is an active and safe regimen for patients with advanced gastric cancer. An Italian Group for the Study of Digestive Tract Cancer (GISCAD) report.
    Zaniboni A; Barni S; Labianca R; Marini G; Pancera G; Giaccon G; Piazza E; Signaroldi A; Legnani W; Luporini G
    Cancer; 1995 Nov; 76(10):1694-9. PubMed ID: 8625036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) in locally advanced or metastatic gastric cancer: a single institution experience.
    Aitini E; Rabbi C; Mambrini A; Cavazzini G; Pari F; Zamagni D; Cantore M; Pagani M; Sorio M; Lusenti A; Adami F; Smerieri F
    Tumori; 2001; 87(1):20-4. PubMed ID: 11669552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for advanced gastric carcinoma.
    Cho EK; Lee WK; Lim DY; Bang SM; Park DK; Park YH; Kwon OS; Choi DJ; Shin DB; Lee JH; Lee TH
    J Korean Med Sci; 2002 Jun; 17(3):348-52. PubMed ID: 12068138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF).
    Findlay M; Cunningham D; Norman A; Mansi J; Nicolson M; Hickish T; Nicolson V; Nash A; Sacks N; Ford H
    Ann Oncol; 1994 Sep; 5(7):609-16. PubMed ID: 7993836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) as neoadjuvant chemotherapy in gastro-oesophageal cancer.
    Melcher AA; Mort D; Maughan TS
    Br J Cancer; 1996 Nov; 74(10):1651-4. PubMed ID: 8932350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of epirubicin, cisplatin, oral uracil and tegafur, and leucovorin in patients with advanced gastric carcinoma.
    Jeen YT; Yoon SY; Shin SW; Kim BS; Mok YJ; Kim CS; Hyun JH; Kim JS; Kim YH
    Cancer; 2001 Jun; 91(12):2288-93. PubMed ID: 11413517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bi-weekly chemotherapy with cisplatin, epirubicin, folinic acid and 5-fluororacil continuous infusion plus g-csf in advanced gastric cancer: a multicentric phase II study.
    Felici A; Carlini P; Ruggeri EM; Gamucci T; Pollera CF; De Marco S; Fariello AM; Moscetti L; Gelibter A; Adami E; Sperduti I; Cognetti F
    Cancer Chemother Pharmacol; 2006 Jan; 57(1):59-64. PubMed ID: 16001173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for esophagogastric adenocarcinoma: response, toxicity, quality of life, and survival.
    Bamias A; Hill ME; Cunningham D; Norman AR; Ahmed FY; Webb A; Watson M; Hill AS; Nicolson MC; O'Brien ME; Evans TC; Nicolson V
    Cancer; 1996 May; 77(10):1978-85. PubMed ID: 8640659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intermittent continuous infusion of 5-fluorouracil in combination with epirubicin and cisplatin in advanced gastric cancer: the importance of dose intensity.
    Poorter RL; Bakker PJ; Fockens P; Taat CW; Bartelsman JF; Veenhof CH
    J Infus Chemother; 1996; 6(2):87-91. PubMed ID: 8809656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized prospective phase II study to compare the combination chemotherapy regimen epirubicin, cisplatin, and 5-fluorouracil with epirubicin, cisplatin, and capecitabine in patients with advanced or metastatic gastric cancer.
    Ocvirk J; Reberšek M; Skof E; Hlebanja Z; Boc M
    Am J Clin Oncol; 2012 Jun; 35(3):237-41. PubMed ID: 21399488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of continuous infusion fluorouracil with epirubicin and cisplatin in patients with metastatic and locally advanced breast cancer: an active new regimen.
    Jones AL; Smith IE; O'Brien ME; Talbot D; Walsh G; Ramage F; Robertshaw H; Ashley S
    J Clin Oncol; 1994 Jun; 12(6):1259-65. PubMed ID: 8201387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study.
    Thuss-Patience PC; Kretzschmar A; Repp M; Kingreen D; Hennesser D; Micheel S; Pink D; Scholz C; Dörken B; Reichardt P
    J Clin Oncol; 2005 Jan; 23(3):494-501. PubMed ID: 15659494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of chemotherapy with 5-fluorouracil, bleomycin, epirubicin, and cisplatin for patients with locally advanced, metastatic, or recurrent undifferentiated carcinoma of the nasopharyngeal type.
    Taamma A; Fandi A; Azli N; Wibault P; Chouaki N; Hasbini A; Couteau C; Armand JP; Cvitkovic E
    Cancer; 1999 Oct; 86(7):1101-8. PubMed ID: 10506692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II study of continuous-infusion 5-fluorouracil with cisplatin and epirubicin in inoperable pancreatic cancer.
    Evans TR; Lofts FJ; Mansi JL; Glees JP; Dalgleish AG; Knight MJ
    Br J Cancer; 1996 May; 73(10):1260-4. PubMed ID: 8630289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of continuous infusional 5-fluorouracil with epirubicin and carboplatin (instead of cisplatin) in patients with metastatic/locally advanced breast cancer (infusional ECarboF): a very active and well-tolerated outpatient regimen.
    Bonnefoi H; Smith IE; O'Brien ME; Seymour MT; Powles TJ; Allum WH; Ebbs S; Baum M
    Br J Cancer; 1996 Feb; 73(3):391-6. PubMed ID: 8562348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of epirubicin, cisplatin and capecitabine combination chemotherapy in patients with metastatic or advanced gastric cancer.
    Cho EK; Lee WK; Im SA; Lee SN; Park SH; Bang SM; Park DK; Park YH; Shin DB; Lee JH
    Oncology; 2005; 68(4-6):333-40. PubMed ID: 16020960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial.
    Cascinu S; Labianca R; Barone C; Santoro A; Carnaghi C; Cassano A; Beretta GD; Catalano V; Bertetto O; Barni S; Frontini L; Aitini E; Rota S; Torri V; Floriani I; ; Pozzo C; Rimassa L; Mosconi S; Giordani P; Ardizzoia A; Foa P; Rabbi C; Chiara S; Gasparini G; Nardi M; Mansutti M; Arnoldi E; Piazza E; Cortesi E; Pucci F; Silva RR; Sobrero A; Ravaioli A
    J Natl Cancer Inst; 2007 Apr; 99(8):601-7. PubMed ID: 17440161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epirubicin, cisplatin, oral UFT, and calcium folinate in advanced gastric carcinoma.
    Kim YH; Kim BS; Seo JH; Choi CW; Kim JS; Chun HJ; Hyun JH; Kim JS
    Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):64-8. PubMed ID: 10442365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of hepatic intraarterial epirubicin and cisplatin, with systemic 5-fluorouracil in patients with unresectable biliary tract tumors.
    Cantore M; Mambrini A; Fiorentini G; Rabbi C; Zamagni D; Caudana R; Pennucci C; Sanguinetti F; Lombardi M; Nicoli N
    Cancer; 2005 Apr; 103(7):1402-7. PubMed ID: 15726542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of epirubicin plus oxaliplatin and infusional 5-fluorouracil as first-line combination therapy in patients with metastatic or advanced gastric cancer.
    Zhang CX; Huang S; Xu N; Fang JW; Shen P; Bao YH; Mou BH; Shi MG; Zhong XL; Xiong PJ
    Anticancer Drugs; 2007 Jun; 18(5):581-6. PubMed ID: 17414627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.